Genetic marker

Deep 6 AI Launches AI-Powered Genomics Module to Accelerate Enrollment for Precision Medicine and Oncology Clinical Trials

Retrieved on: 
Wednesday, September 6, 2023
Heart, EMR, Personalized medicine, Clinical trial, Record, Research, Genomics, Genetic marker, Marker beacon, Patient, IRB, Medicine, Ecosystem, NCI, Gene, Disease, Software, Medical device

PASADENA, Calif., Sept. 6, 2023 /PRNewswire/ -- Deep 6 AI, the leading AI-powered clinical trial acceleration software, announces the launch of its genomics module to accelerate enrollment for precision medicine and oncology research. The software uses AI to mine genomics data across an entire electronic medical record (EMR) system and disparate genetic reports to find patients with specific genetic markers in real time. Now, healthcare organizations and life sciences companies can precision-match patients to clinical trials based on their complete clinical and genomic profile, improving trial design, feasibility, and recruitment.

Key Points: 
  • PASADENA, Calif., Sept. 6, 2023 /PRNewswire/ -- Deep 6 AI , the leading AI-powered clinical trial acceleration software, announces the launch of its genomics module to accelerate enrollment for precision medicine and oncology research.
  • Deep 6 AI's CEO, Wout Brusselaers, commented: "Genetic markers have become increasingly important in determining a patient's eligibility for precision medicine and oncology clinical trials.
  • "Precision medicine and oncology trials require precise patient matching—and that's at the heart of what we do," said Deep 6 AI's CEO, Wout Brusselaers.
  • Applying our AI to genomics data will accelerate and de-risk research and bring life-changing therapies to patients faster."

Improved analytic workflows in new version of JMP statistical products

Retrieved on: 
Tuesday, October 18, 2022
API, Murata, Hierarchy, Central Statistics Office (India), Data integration, EMP, National Museum of Marine Biology and Aquarium, POWER, Review, List of national museums, CARY, Workflow, Intelligence, MSA, OSI, Genetic marker, Science, SAS Institute Inc v World Programming Ltd, Multivariate, Automation, DOE, Decision-making, Software, Publishing, Dairygold, Education, Health, Cheese, Gold, Genetic, Thermo Fisher Scientific, Clinical trial, The Narrative Design Explorer, JMP, Regeneron Pharmaceuticals, OSIsoft, Name, Data analysis, AIAG, Marine biology, Continued process verification, SAS, Pharmaceutical industry, Risk management, Feed manufacturing, Typesetting, Online shopping, Satellite navigation device

CARY, N.C., Oct. 18, 2022 /PRNewswire/ -- While a dairy scientist, a process engineer and a tech innovator have varying domain knowledge, they all rely on the JMP® family of statistical discovery products to meet modern data challenges. JMP 17, JMP Pro 17 and JMP Live 17 are launched today, after first being introduced at the Discovery Summit Americas analytics conference. The products enable scientists and engineers with intuitive and collaborative analytic workflows, whether they are in business to process raw materials into cheese, ensure drug manufacturing meets regulatory standards or develop sensors for autonomous vehicles.

Key Points: 
  • JMP 17, JMP Pro 17 and JMP Live 17 are launched today, after first being introduced at the Discovery Summit Americas analytics conference.
  • JMP 17, JMP Pro 17 and JMP Live 17 launched today after being introduced at the Discovery Summit Americas conference.
  • Consumer products organization Dairygold sees JMP as a process-enabling tool, not just software, explained Science and Analytics Manager Kieran O'Mahony.
  • JMP and all other JMP Statistical Discovery LLC product or service names are registered trademarks or trademarks of JMP Statistical Discovery LLC in the USA and other countries.

Prolonging healthspan by delaying ageing -- NUHS opens Singapore's first Centre for Healthy Longevity to increase healthy lifespan of Singapore population by five more disease-free years

Retrieved on: 
Wednesday, September 7, 2022
Longevity, Inflammation, Yong Loo Lin School of Medicine, Metabolomics, Conditional sentence, Osteoarthritis, CEO, Foundation for the National Institutes of Health, Cancer, Research, Life expectancy, Degenerative disease, Exercise, Disease, National University of Singapore, Death, Gym and Tonic, Health, National University Health System, DNA, Intelligence, Prognosis, Alexandra Hospital, DNA methylation, Multimedia, Foundation, Genome, Adoption, Association, Age, Medicine, Biology, Prevalence, TRP, Population, Therapy, Life, Biomarker, Dementia, NUHS, Geroprotector, Knowledge, Invention, Risk, Sarcopenia, Genetic marker, CHL, Climate change, National university, Pharmaceutical industry, Vaccine, Health insurance, Dietary supplement

SINGAPORE, Sept. 7, 2022 /PRNewswire/ -- Ageing is the climate change in medical science, where global societies are experiencing a sharp rise in the number of older adults relative to the rest of the population. Singapore will be the fastest country by 2025, with 25% of its population estimated to be above 65 years old by 2030. Although medical advancement has improved life expectancy among Singaporeans by 8.7 years to 84.8 years, one of the longest in the world; our healthy life expectancy, or healthspan, increased by only 7.2 years to 74.2 years. The grim reality is that Singaporeans are spending about 10 years of their twilight years in poor health. As the gap between life expectancy and health adjusted life expectancy increases, healthcare and caregiving costs will represent an unsustainable socioeconomic burden for society.

Key Points: 
  • The Centre will focus on key geroscience projects, and develop and validate ageing 'clocks' in the Singapore population, and to test the efficacies of novel geroprotectors in delaying biological ageing and enhancing healthspan.
  • Singapore will be the fastest country by 2025, with 25% of its population estimated to be above 65 years old by 2030.
  • The grim reality is that Singaporeans are spending about 10 years of their twilight years in poor health.
  • 2 NUHS CHL has one clear mission: to enhance healthspan by five years in the Singapore population by slowing biological ageing.

Basepaws Adds Over 80 Genetic Markers To Its Cat DNA Test

Retrieved on: 
Monday, November 15, 2021
Knowledge, Genetic, HCM, Health, Degenerative disease, Gene, Technology, Periodontal disease, Multimedia, Hypertrophic cardiomyopathy, Tooth resorption, Parent, D2C, Genetic marker, DNA, Risk, Cat, Animal, Pet

LOS ANGELES, Nov. 15, 2021 /PRNewswire/ -- Basepaws , the creator of the world's first at-home Breed + Health Cat DNA test and leading innovator in pet health biotechnology, announced today that it updated its flagship product with over 80 new genetic health and trait markers.

Key Points: 
  • LOS ANGELES, Nov. 15, 2021 /PRNewswire/ -- Basepaws , the creator of the world's first at-home Breed + Health Cat DNA test and leading innovator in pet health biotechnology, announced today that it updated its flagship product with over 80 new genetic health and trait markers.
  • "Basepaws is proud to offer the most comprehensive cat DNA test on the market," said Yuliana Mihaylova, Ph.D., Basepaws Head of R&D.
  • The upgraded digital report for the Basepaws Cat DNA test will include the following:
    Over 70 known feline genetic health markers, including new markers for feline ophthalmological conditions and hypertrophic cardiomyopathy (HCM), the most common form of heart disease in cats;
    Genetic markers for blood type.
  • Launched in 2018, the Basepaws at-home Breed + Health Cat DNA Test became the first-of-its-kind.